LLY Club name Eli Lilly is staying busy on M&A, scooping up companies working on a variety of conditions and diseases away from its current
LLY Club name Eli Lilly is staying busy on M&A, scooping up companies working on a variety of conditions and diseases away from its current cash cow of obesity. The latest target: psychedelic drugmaker AtaiBeckley. Lilly is paying $2.8B upfront for the company, which has a depression treatment that has started late-stage trial activities. - per Cramer Investing Club Newsletter
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.